New gel could shrink neurofibroma tumors without surgery

NCT ID NCT05005845

Completed Disease control Sponsor: NFlection Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a gel called NFX-179 on skin tumors in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 26 weeks. The study measured safety and whether tumors shrank in size or height. Results suggest the gel may help reduce tumor volume, but more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NFX-179 gel
What this could lead to: If successful, this gel could offer a non-surgical way to shrink or control skin tumors in people with neurofibromatosis type 1.
What could go wrong: This is a phase 2 trial with a small number of participants. The gel may not work for everyone, and long-term effects are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibroma neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS NEUROFIBROMA NEUROFIBROMATOSIS 1

Contacts and locations

Locations

Apex Clinical Research Center, LLC

Mayfield Heights, Ohio, 44124, United States
Center for Dermatology Clinical Research, Inc.

Fremont, California, 94538, United States
Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's National Hospital

Washington D.C., District of Columbia, 20010, United States
Dawes Fretzin Clinical Research Group

Indianapolis, Indiana, 46250, United States
Derm Dox Center for Dermatology

Sugarloaf, Pennsylvania, 18249, United States
Dermatology Treatment and Research Center

Dallas, Texas, 75230, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Minnesota Clinical Study Center

New Brighton, Minnesota, 55112, United States
Northshore University HealthSystem

Evanston, Illinois, 60077, United States
Northwest Arkansas Clinical Trials Center, PLLC

Rogers, Arkansas, 72758, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Sadick Research Group, LLC

New York, New York, 10075, United States
Skin Search of Rochester, Inc.

Rochester, New York, 14623, United States
Skin Specialists, P.C.

Omaha, Nebraska, 68144, United States
The Education & Research Foundation, Inc.

Lynchburg, Virginia, 24501, United States
The Johns Hopkins School of Medicine

Baltimore, Maryland, 21287, United States
UTHealth McGovern Medical School

Houston, Texas, 77030, United States
University Clinical Trials, Inc.

San Diego, California, 92123, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205-7199, United States
University of Florida

Gainesville, Florida, 32610, United States
University of Utah

Salt Lake City, Utah, 84108, United States
Wake Forest School of Medicine

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.